Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

An unmet need exists for effective, well-tolerated, and convenient treatment (tx) options in patients (pts) with high-risk relapsed/refractory (R/R) follicular lymphoma (FL), including double refractory pts (refractory to anti-CD20 tx and an alkylating agent) and pts with disease progression within 2 y of first-line (1L) immunochemotherapy (POD24). Epcoritamab, a subcutaneous (SC) CD3xCD20 bispecific antibody, is approved in the US for adults with R/R diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic tx.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Kim M Linton, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Herve Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Umberto Vitolo, Tara Cochrane, Tags: 38 Source Type: research